Fortis Gurugram Marks 2500 Bone Marrow Transplants Transforming Lives Through Advanced Blood Disorder Care

Fortis Gurugram Marks 2,500 Bone Marrow Transplants, Transforming Lives Through Advanced Blood Disorder Care

- Landmark milestone highlights the evolution of Bone Marrow 

Transplantation from a highly specialised treatment to a life-saving and potentially curative therapy for thousands of patients -

Delhi NCR, 30 June 2026: Fortis Memorial Research Institute (FMRI), Gurugram has achieved a 
landmark milestone of successfully performing over 2,500 Bone Marrow Transplants (BMTs) across 
adult and paediatric patients, reinforcing its position as one of India's leading centres for Blood and 
Marrow Transplantation.

More than a clinical achievement, the milestone represents thousands of patients and families who 
found hope, healing and, in many cases, a cure for life-threatening blood cancers and complex blood 
disorders. Over the years, the programme has helped transform outcomes for patients suffering from 
leukaemia, lymphoma, multiple myeloma, aplastic anaemia, thalassaemia, sickle cell disease, myelodysplastic syndromes, immune deficiency disorders and several rare haematological conditions.

Bone Marrow Transplantation has undergone a remarkable transformation over the past decade. Once considered a highly specialised and last-resort treatment available to only a limited number of patients, it has evolved into a precision-driven curative therapy supported by advances in genomics, donor matching, cellular therapies and personalised treatment protocols. Innovations such as haploidentical (half-matched) donor transplantation, high-resolution HLA typing, minimal residual disease (MRD)-guided treatment decisions, genomic risk stratification, post-transplant cyclophosphamide for graft-versus-host disease prevention, and CAR-T Cell Therapy have significantly improved outcomes and expanded access to transplantation.

At Fortis Gurugram, the BMT programme is supported by a multidisciplinary team of haematologists, 
haemato-oncologists, paediatric transplant specialists, molecular diagnostics experts, transfusion 
medicine specialists, infectious disease physicians, intensivists, nurses, nutritionists and rehabilitation 
professionals. The centre has also emerged as a preferred destination for international patients, 
having successfully treated patients from many countries, primarily from Africa, seeking advanced and 
affordable transplant care.

Speaking on the milestone, Dr Rahul Bhargava, Principal Director & Chief – Haematology, HaematoOncology & Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram, said: "Crossing 2,500 Bone Marrow Transplants is not merely a numerical milestone; it represents 2,500 lives touched and countless families given renewed hope. Every transplant is a journey that requires clinical 
expertise, technological innovation, multidisciplinary teamwork and extraordinary resilience from patients and their families. What is particularly encouraging is how transplantation has evolved over the years. Today, many conditions that were once considered extremely difficult to treat can be managed with curative intent. Our focus remains on expanding access to these advanced therapies while continuing to improve outcomes through precision medicine, genomics and cellular therapies."

Dr Vikas Dua, Principal Director & Head – Paediatric Haematology, Haemato-Oncology & BMT, Fortis Memorial Research Institute, Gurugram, said: "For children diagnosed with blood cancers, thalassaemia, aplastic anaemia and immune deficiency disorders, Bone Marrow Transplantation can be life-changing and often life-saving. Beyond survival, our goal is to help children return to school, regain their childhood and live healthy, productive lives. This milestone reflects the strength of our integrated paediatric and adult transplant programme and our commitment to delivering world-class care to families from India and around the world."

Mr Yash Rawat, Senior Vice President & SBU Head, Fortis Memorial Research Institute, Gurugram, 
said: "This milestone reflects Fortis Healthcare's long-standing commitment to building specialised 
clinical programmes that deliver meaningful patient outcomes. India has made remarkable progress 
in Bone Marrow Transplantation through improved expertise, expanding infrastructure, better donor 
availability and growing awareness. At FMRI, we remain focused on strengthening our capabilities in 
haematology, transplantation, cellular therapy and precision medicine so that more patients can 
access life-saving treatment closer to home."

The milestone is reflected not only in the number of transplants performed but also in the lives 
transformed through the programme. Among them is three-year-old Treya Chrisley, who travelled to 
India after being diagnosed with relapsed B-cell Acute Lymphoblastic Leukaemia (ALL). Following a 
successful stem cell transplant at Fortis Memorial Research Institute, Gurugram, she is now recovering 
well and has crossed Day 52 post-transplant. Expressing their gratitude, her family said, "When our 
daughter was diagnosed with relapsed ALL, every path led us to Fortis in India. The entire Bone Marrow 
Transplant team stood by us through every step of the journey, treating us like family. Their expertise, 
compassion and unwavering support have given our daughter a second chance at life and given us 
hope for the future."

The programme has also enabled long-term recovery for patients from across the globe. Muleme 
Elisha Isaiah from Uganda underwent a Bone Marrow Transplant at Fortis Gurugram in 2018. Today, 
the 10-year-old leads an active and healthy life, attends primary school, plays football for his school 
team and enjoys riding his bicycle every day. Sharing his experience, Isaiah said, "I feel good and 
strong." His journey reflects the long-term success of Bone Marrow Transplantation and the possibility 
of children returning to a normal, healthy childhood after treatment.

As the demand for advanced blood disorder treatment continues to grow, Fortis Gurugram aims to 
further strengthen its Bone Marrow Transplantation, cellular therapy, genomics and precision medicine programmes, while continuing to improve access, survival outcomes, and long-term quality of life for patients across India and internationally.